Associated Papers
Tramadol-related fatalities: Metabolic ratios & SNPs/INDELs belonging to UGT1A8, UGT2B7, ABCC2, and SLC22A1.
Aly SM et al.
Forensic Science International. Genetics, 2025
In silico and biological analyses of missense variants of the human biliary efflux transporter ABCC2: effects of novel rare missense variants.
Kölz C et al.
British Journal of Pharmacology, 2024
Single-Nucleotide Polymorphisms Associated with Mercury Levels and Neurological Symptoms: An Overview.
Perini JA et al.
Toxics, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Case report: Acute liver failure during deferasirox therapy and the potential role of pharmacogenetics.
García-Fariña B et al.
Frontiers in Pharmacology, 2024
Molecular and Clinical Links between Drug-Induced Cholestasis and Familial Intrahepatic Cholestasis.
Vitale G et al.
International Journal of Molecular Sciences, 2023
Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy.
Sharma P et al.
Journal of Biochemical and Molecular Toxicology, 2023
Blood ACE Phenotyping for Personalized Medicine: Revelation of Patients with Conformationally Altered ACE.
Danilov SM et al.
Biomedicines, 2023
Impact of ABCB1, ABCC1, ABCC2, and ABCG2 variants in predicting prognosis and clinical outcomes of north Indian lung cancer patients undergoing platinum-based doublet chemotherapy.
Sharma P et al.
The Journal of Gene Medicine, 2023
Pharmacogenetics of Drug Metabolism: The Role of Gene Polymorphism in the Regulation of Doxorubicin Safety and Efficacy.
Bagdasaryan AA et al.
Cancers, 2022
Population-based meta-analysis and gene-set enrichment identifies FXR/RXR pathway as common to fatty liver disease and serum lipids.
Handelman SK et al.
Hepatology Communications, 2022
Expanding the prostate cancer cell line repertoire with ACRJ-PC28, an AR-negative neuroendocrine cell line derived from an African-Caribbean patient.
Valentine H et al.
Cancer Research Communications, 2022
Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.
Pinto-Merino Á et al.
Pharmaceutics, 2022
Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine.
Yip VLM et al.
British Journal of Clinical Pharmacology, 2021
Pharmacogenetics Approach for the Improvement of COVID-19 Treatment.
Fricke-Galindo I et al.
Viruses, 2021
The association of transporter ABCC2 (MRP2) genetic variation and drug-induced hyperbilirubinemia.
Huang YS et al.
Journal of the Chinese Medical Association : Jcma, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma.
Maillard M et al.
Cancers, 2020
Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity.
Cabral LKD et al.
Cancers, 2020
A recurrent ABCC2 p.G693R mutation resulting in loss of function of MRP2 and hyperbilirubinemia in Dubin-Johnson syndrome in China.
Wu L et al.
Orphanet Journal of Rare Diseases, 2020
New tight junction protein 2 variant causing progressive familial intrahepatic cholestasis type 4 in adults: A case report.
Wei CS et al.
World Journal of Gastroenterology, 2020
Genetic Polymorphisms and the Efficacy of Platinum-Based Chemotherapy: Review.
Afifah NN et al.
Pharmacogenomics and Personalized Medicine, 2020
Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease.
Cafiero C et al.
Pharmacogenomics and Personalized Medicine, 2020
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?
Nichetti F et al.
The Pharmacogenomics Journal, 2019
Enantiospecific Pharmacogenomics of Fluvastatin.
Hirvensalo P et al.
Clinical Pharmacology and Therapeutics, 2019
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
An African-specific profile of pharmacogene variants for rosuvastatin plasma variability: limited role for SLCO1B1 c.521T>C and ABCG2 c.421A>C.
Soko ND et al.
The Pharmacogenomics Journal, 2019
Pediatric Anthracycline-Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem-Cell Modeling.
Tripaydonis A et al.
Clinical Pharmacology and Therapeutics, 2019
Germline variants in cancer therapy.
Kaehler M et al.
Cancer Drug Resistance (alhambra, Calif.), 2019
ATP-Binding Cassette Transporters in the Clinical Implementation of Pharmacogenetics.
López-Fernández LA
Journal of Personalized Medicine, 2018
Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.
Baxi SM et al.
The Pharmacogenomics Journal, 2018
Unexplained cholestasis in adults and adolescents: diagnostic benefit of genetic examination.
Aamann L et al.
Scandinavian Journal of Gastroenterology, 2018
Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer.
Gao B et al.
Scientific Reports, 2018
The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
Lloberas N et al.
Pharmacogenetics and Genomics, 2017
In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants.
Wen X et al.
Pharmaceutical Research, 2017
MRP2/ABCC2 C1515Y polymorphism modulates exposure to lumefantrine during artemether-lumefantrine antimalarial therapy.
Vos K et al.
Pharmacogenomics, 2017
Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE et al.
Leukemia & Lymphoma, 2017
Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.
Leong SL et al.
Scientific Reports, 2017
Advances and challenges in hereditary cancer pharmacogenetics.
Cascorbi I et al.
Expert Opinion on Drug Metabolism & Toxicology, 2017
Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?
Magdy T et al.
Pharmacology & Therapeutics, 2016
Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.
Chen S et al.
Drug Metabolism Reviews, 2016
Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers.
Fricke-Galindo I et al.
Pharmacogenomics, 2016
ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.
Cuffe S et al.
Cancer Epidemiology, 2016
Genetic analysis of nonalcoholic fatty liver disease within a Caribbean-Hispanic population.
Edelman D et al.
Molecular Genetics & Genomic Medicine, 2015
Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples.
Edavana VK et al.
International Journal of Cancer Research and Molecular Mechanisms, 2015
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine.
Simeon V et al.
International Journal of Molecular Sciences, 2015